Arthur Levin, PhDExecutive Vice President, R&D at Avidity Biosciences LLC
Arthur Levin is a key opinion leader in the RNA therapeutics field. He serves as the CSO at Avidity Biosciences. Previously, he held Senior levels positions at mRiragen, Santaris Pharma, and Ionis Pharmaceuticals. He played key roles in developing numerous of oligonucleotides including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials. He has three decades of experience in drug development from discovery through drug registration. Dr. Levin has published over 60 scientific articles and several of the most cited reviews in the field. He is on the scientific advisory boards of multiple institutions. Art received a doctorate in toxicology from the University of Rochester.